Patents by Inventor Allen J. Ebens

Allen J. Ebens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
    Patent number: 9335320
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: May 10, 2016
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Lori Friedman
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20150166661
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 18, 2015
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, JR., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU, Liping L. SUN
  • ANTI-FCRH5 ANTIBODIES
    Publication number: 20150098900
    Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 24, 2014
    Publication date: April 9, 2015
    Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
  • Anti-CD22 antibodies and immunoconjugates and methods of use
    Patent number: 8968741
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 3, 2015
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20140128580
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 8, 2014
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
  • Antibody-drug conjugates and methods
    Patent number: 8652479
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: February 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Frederic S. Jacobson, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES
    Publication number: 20130330765
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 15, 2013
    Publication date: December 12, 2013
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Lori Friedman
  • Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
    Patent number: 8536161
    Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: September 17, 2013
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Lori Friedman
  • Antibodies and immunoconjugates and uses therefor
    Patent number: 8524865
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: September 3, 2013
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20130171170
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Application
    Filed: June 12, 2012
    Publication date: July 4, 2013
    Applicant: GENENTECH, INC.
    Inventors: ALLEN J. EBENS, JR., ALANE M. GRAY, WEI-CHING LIANG, YAN WU, SHANG-FAN YU
  • 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
    Patent number: 8435976
    Abstract: The invention relates to compounds of formula (I) which are useful as kinase inhibitors, more specifically useful as PIM kinase inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same, either alone or in combination, to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: May 7, 2013
    Assignee: F. Hoffmann-La Roche
    Inventors: Xiaojing Wang, Allen J. Ebens, Jr.
  • Anti-CD22 antibodies and immunoconjugates and methods of use
    Patent number: 8394607
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: March 12, 2013
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 8388973
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: March 5, 2013
    Assignee: Genentech, Inc.
    Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • Anti-CD22 Antibodies And Immunoconjugates and Methods of Use
    Publication number: 20120329094
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Application
    Filed: July 26, 2012
    Publication date: December 27, 2012
    Applicant: Genentech, Inc.
    Inventors: Allen J. Ebens, JR., Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • Antibodies and immunoconjugates and uses therefor
    Patent number: 8226945
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: July 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120148608
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 14, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120148610
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 14, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141508
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141509
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20120141510
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 7, 2012
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer